← Back to Search

Glycogen Synthase Kinase 3 Beta Inhibitor

Tideglusib for Myotonic Dystrophy

Phase 2 & 3
Waitlist Available
Research Sponsored by AMO Pharma Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 22 to 28 weeks

Summary

This trial is testing tideglusib, a medication, to see if it can help children with a genetic muscle disorder. The study involves children aged 6 to 16 who have Congenital Myotonic Dystrophy. Tideglusib might work by blocking a substance that causes muscle issues.

Eligible Conditions
  • Myotonic Dystrophy, Congenital

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~22 to 28 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 22 to 28 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS)
Secondary study objectives
10-meter walk-run test
Caregiver Completed Congenital DM1 Rating Scale (CC-CDM1-RS)
Change in Clinical Global Impression- Improvement Scale (CGI-I) scores
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TideglusibExperimental Treatment2 Interventions
Weight adjusted tideglusib, orally, once daily
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo, orally, once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
Tideglusib
2016
Completed Phase 3
~160

Find a Location

Who is running the clinical trial?

AMO Pharma LimitedLead Sponsor
2 Previous Clinical Trials
92 Total Patients Enrolled
2 Trials studying Myotonic Dystrophy
92 Patients Enrolled for Myotonic Dystrophy
Joseph P Horrigan, MDStudy DirectorAMO Pharma
1 Previous Clinical Trials
76 Total Patients Enrolled
1 Trials studying Myotonic Dystrophy
76 Patients Enrolled for Myotonic Dystrophy
~12 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top